(12) **Translation of European patent specification**

(11) **NO/EP 2629776 B1**

NORWAY

(19) NO

(51) Int Cl.

C07D 401/04 (2006.01)
A61K 31/506 (2006.01)
A61P 3/08 (2006.01)
A61P 9/00 (2006.01)
A61P 25/28 (2006.01)
A61P 35/00 (2006.01)
C07D 401/14 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2018.02.05
(80)	Date of The European Patent Office Publication of the Granted Patent	2017.08.16
(86)	European Application Nr.	11835025.5
(86)	European Filing Date	2011.10.18
(87)	The European Application's Publication Date	2013.08.28
(30)	Priority	2010.10.18, US, 394136 P 2011.02.18, US, 201161444212 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Cerenis Therapeutics Holding SA, Rue De La Découverte - Bât. A, 31670 Labege Cedex, FR-Frankrike
(72)	Inventor	ONICIU, Daniela Carmen, 18 Rue Sainte AnneAppt. 302, 31000 Toulouse, FR-Frankrike DASSEUX, Jean-Louis Henri, 7 Allees Charles MalpeBat. B 406, 31300 Toulouse, FR-Frankrike BARBARAS, Ronald, 22bis Avenue du Grand Plantier, 31840 Seilh, FR-Frankrike KOCHUBEY, Valery, 8 Solovyinaya RoschaApt. 76, 125466 Moscow, RU-Russland KOVALSKY, Dmitry, 88 NovomytischinskyProspectBuilding 1, Apt. 130, 141018 Mytischi, RU-Russland RODIN, Oleg Gennadievich, 3 KantemirovskayaBuilding 6, Apt 68, 115304 Moscow, RU-Russland GEOFFROY, Otto, 4306 NW 35th Street, Gainesville, Florida 32605, US-USA RZEPIELA, Anna, Strijplaan 156, 2285 HV Rijswijk, NL-Nederland
(74)	Agent or Attorney	Tandberg Innovation AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54) Title **COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILISATION**

(56) References

Cited: WO-A1-2009/046606, ZHAN C. ET AL.: 'Molecular modeling of purinergic receptor P2Y12 and interaction with its antagonists' JOURNAL OF MOLECULAR GRAPHIES AND MODELLING vol. 26, no. 1, 2007, pages 20 - 31, XP022132983, WO-A2-2007/143724, WO-A2-2012/054535, US-A- 3 935 222, US-A- 3 939 159, US-A- 5 288 726, US-A- 5 763 448, US-A1- 2007 249 555, US-B1- 6 632 814, KIM Y C ET AL: "Synthesis of pyridoxal phosphate derivatives with antagonist activity at the P2Y13 receptor", BIOCHEMICAL PHARMACOLOGY, ELSEVIER, US, vol. 70, no. 2, 15 July 2005 (2005-07-15), pages 266-274, XP027715534, ISSN: 0006-2952 [retrieved on 2005-07-15], DATABASE REGISTRY [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 25 March 2010 (2010-03-25), XP002724959, Database accession no. 1214529-66-4, DATABASE REGISTRY [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 7 September 2010 (2010-09-07), XP002724960, Database accession no. 1240167-51-4, DATABASE REGISTRY [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 25 March 2010 (2010-03-25), XP002724961, Database accession no. 1214614-28-4, WO-A2-2005/076007

Patentkrav

1. En forbindelse som har strukturen:

IIa:  ; IIb:  ;

IIc:  ; IId 

IIe:  IIf: 

IIg:  IIh: 

IIi:  IIj: 

IIk: 

IIl: 

IIm: 

IIn: 

IIo: 

IIp: 

IIq: 

IIr: 

IIs:  ;

IIt:  ;

IIu:  ; IIv:  ;

IIw:  ; IIx:  ;

IIy:  ; IIz: 

IIaa  ; IIbb  ;

IIcc:  ; IIdd:  ;

IIee:  ; IIff:  ;

IIgg:  ; IIhh:  ;

IIii:  ; or IIjj:  ,

eller et farmasøytisk akseptabelt salt av en hvilken som helst av de foregående.

2. En forbindelse ifølge krav 1 som har strukturen:

IIa:



eller et farmasøytisk akseptabelt salt derav.

3. En sammensetning som omfatter en effektiv mengde av en forbindelse eller farmasøytisk akseptabelt salt av forbindelsen ifølge krav 1 eller krav 2 og et farmasøytisk akseptabelt vehikkel eller bærer.

4. Sammensetningen ifølge krav 3, hvor sammensetningen er formulert for oral administrering.

5. Sammensetningen ifølge krav 3 hvor sammensetningen er i form av en tablett eller kapsel.

6. Sammensetningen ifølge krav 3, hvor forbindelsen eller salt derav er tilstede i en mengde på rundt 1 mg til rundt 1,000 mg.

7. En forbindelse ifølge krav 1 eller krav 2 eller et farmasøytisk akseptabelt salt derav for anvendelse ved behandling av en lidelse, hvor lidelsen er en hepatisk steatose, en kardiovaskulær lidelse, en lidelse i lipoprotein-metabolismen, en lidelse i glukose-metabolismen, inflammasjon, iskemisk nekrose, kolonkreft, lungekreft, brystkreft, hudkreft, en trombotisk lidelse, Alzheimers sykdom, Parkinsons sykdom, pankreatitt, eller unormal galleproduksjon.

8. Anvendelsen en forbindelse ifølge krav 1 eller krav 2 eller et farmasøytisk akseptabelt salt derav i fremstillingen av et medikament for behandlingen av en lidelse, hvor lidelsen er en hepatisk steatose, en kardiovaskulær lidelse, en lidelse i lipoprotein-metabolismen, en lidelse i glukosemetabolismen, inflammasjon, iskemisk nekrose, kolonkreft, lungekreft, brystkreft, hudkreft, en trombotisk lidelse, Alzheimers sykdom, Parkinsons sykdom, pankreatitt, eller unormal galleproduksjon.